EX1A-6 MAT CTRCT 6 ea021572001ex6-2_noktherap.htm PATENT CONFIRMATION ASSIGNMENT

Exhibit 6.2

 

Patent Confirmation Assignment

 

This patent confirmation assignment (the “Assignment”) is entered into by and between:

 

(1)The bankruptcy estate of XNK Therapeutics AB (publ), reg. no. 556894-6601, c/o Advokatfirma DLA Piper Sweden KB Box 7315, 103 90 Stockholm, Sweden (the “Bankruptcy Estate”); and

 

(2)NÖK Therapeutics Inc., a company incorporated and registered in the United States of America, 1452 N. US Hwy. 1, Suite 123, Ormond Beach, FL 32174 (the “Buyer”).

 

The above parties are hereinafter jointly referred to as the “Parties” and each individually as a “Party”.

 

BACKGROUND

 

(a)XNK Therapeutics AB, reg. no. 556894-6601, (the “Company”), a limited liability company construed under the laws of Sweden, was declared bankrupt on 9 April 2024, and certain parts of the Company’s assets were subsequently sold by the Bankruptcy Estate to the Buyer under patent transfer and assignment agreement (the “Agreement”), dated 23 May 2024 (the “Effective Date”).

 

(b)As part of the Agreement, the terms of which are otherwise confidential, it was agreed that the patents listed in Schedule 1 (the “Patents”) should be assigned and transferred to the Buyer, including all right, titles and interests to the Patents.

 

(c)The Parties are therefore executing this Assignment in order to confirm and record the transfer of the Patents from the Bankruptcy Estate to the Buyer with the relevant patent offices.

 

In light of the above, the Parties confirm and agree the following.

 

1.ASSIGNMENT

 

Pursuant to and for the consideration set out in the Agreement, the Bankruptcy Estate hereby confirms that, with effect from the Effective Date, it has assigned and transferred to the Buyer, which the Buyer has accepted, the Patents, including, without limitation, the absolute right, titles and interests in and to the Patents, and in and to all and any inventions disclosed in the Patents.

 

2.FURTHER ASSURANCE

 

Each Party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

 

3.RELATIONSHIP TO THE HEAD AGREEMENT

 

This Assignment is entered into for confirmatory and recording purposes and any and all provisions of the Agreement remain in full force and effect.

 

[Signature page to follow]

 

DLA Piper   |  1

 

 

The Assignment has been executed in one (1) or multiple copies and signed digitally. Each such signed copy shall be deemed an original and all of which together shall constitute one and the same Assignment, of which each Party shall receive a PDF copy.

 

Bankruptcy Estate

 

NÖK Therapeutics Inc. 

     
/s/ Anders Svensson Clark   /s/ David Mehalick
Anders Svensson Clark   David Mehalick

 

DLA Piper   |  2

 

 

Schedule 1

 

“Patents”

 

Title: Expansion of NK Cells

Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB

Country   Inventor(s)   Appl. No.   Appl. Date   Reg. no.   Reg. date   Renewal Date   Status
Belgium   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Czech Republic   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Denmark   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Finland   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
France   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Germany   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Ireland   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Italy   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Luxemburg   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
the Netherlands   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Norway   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Poland   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Portugal   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Spain   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Sweden   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Switzerland   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
Turkey   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
UK   Evren Alici   EP10756430   25 Mar 2010   EP2411507   25 Sept 2019   25 Mar 2025   Granted
                             
[Intentionally left blank]
China   Evren Alici   CN 201080021237.8   2010-03-25   CN 102428173           Granted
                             
Hong Kong   Evren Alici   HK 12110647.2   2010-03-25   HK 1170258   20 Mar 2015   25 Mar 2025   Granted
                             
Japan   Evren Alici   JP 2017-208238   2010-03-25   JP 2018-046840       25 Mar 2025   Granted
                             
Republic of Korea   Evren Alici   KR 10-2011-7025234   2010-03-25   1018815200000   18 July 2018   5 July 2024   Granted
                             
USA   Evren Alici   US 13/260,004   25 Mar 2010   US 8,877,182   4 Nov 2014   25 Mar 2026   Granted

 

DLA Piper   |  3

 

 

Title: Expanded NK Cells

Applicant/owner: Cellprotect Nordic Pharmaceuticals AB

Country   Inventor(s)   Appl. No.   Appl. Date   Reg. no.   Reg. date   Renewal Date   Status
USA   Sirac Dilber, Evren Alici   US 14/830,758   20 Aug 2015   US 9,585,914   7 March 2017  

1 maint. fee paid 2020

2 maint. fee to be paid 7-7,5 years after issue date 

  Granted

 

Title: Medical Uses

Applicant/owner: XNK Therapeutics AB

Country   Inventor(s)   Appl. No.   Appl. Date   Reg. no.   Reg. date   Renewal Date   Status
China  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

  CN 201980029357.3   30 April 2019               Pending
                             
EP  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

  EP 3787685   30 April 2019               Pending
                             
Hong Kong  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

Ljunggren

  62021036993.5   30 April 2019               Pending
                             
Hong Kong  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

  62021038634.3   30 April 2019               Pending
                             
Japan  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

  JP 2021-510533   30 April 2019               Pending
                             
Republic of Korea  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

 

KR 10-2020-7034431

  30 April 2019               Pending
                             
US  

Evren Alici, Hareth Nahi,

Carl Arnold Gösta Gahrton, Hans-Gustaf Einar Ljunggren

  17/04,8702   30 April 2019               Pending

 

Title: Methods

Applicant/owner: XNK Therapeutics AB

Country   Inventor(s)   Appl. No.   Appl. Date   Reg. no.   Reg. date   Renewal Date   Status
PCT   Jan Per-Henrik Holmqvist   PCT/GB2022/079547   24 Oct 2022   N/A   N/A   N/A   EP and USA has been designated.

 

DLA Piper   |  4